Novel separation method for highly sensitive speciation of cancerostatic platinum compounds by HPLC–ICP–MS
A high-performance liquid chromatography–inductively coupled plasma mass spectrometry (HPLC–ICP–MS) method is presented for analysis of cisplatin, monoaquacisplatin, diaquacisplatin, carboplatin, and oxaliplatin in biological and environmental samples. Chromatographic separation was achieved on pentafluorophenylpropyl-functionalized silica gel. For cisplatin, carboplatin, and oxaliplatin limits of detection of 0.09, 0.10, and 0.15 μg L−1, respectively, were calculated at m/z 194, using aqueous standard solutions. (3 μL injection volume). The method was utilized for model experiments studying the stability of carboplatin and oxaliplatin at different chloride concentrations simulating wastewater and surface water conditions. It was found that a high fraction of carboplatin is stable in ultrapure water and in solutions containing 1.5 mol L−1 Cl−, whereas oxaliplatin degradation was increased by increasing the chloride concentration. In order to support the assessment of oxaliplatin eco-toxicology, the method was tested for speciation of patient urine. The urine sample contained more than 17 different reaction products, which demonstrates the extensive biotransformation of the compound. In a second step of the study the method was successfully evaluated for monitoring cancerostatic platinum compounds in hospital waste water.
KeywordsCisplatin Carboplatin Oxaliplatin Wastewater Urine Stability study
Financial support was granted through the Austrian Science Fund (FWF-Project P16089-N03: “Speciation of cancerostatic Pt compounds in the environment”). Professor Robert Mader (Vienna University Hospital) is gratefully acknowledged for sampling of patient urine.
- 2.Pineto HM, Schornagel JH (eds) (1996) Platinum and other metal coordination compounds in cancer chemotherapy 2. Plenum, New YorkGoogle Scholar
- 4.Allwood M, Stanley A, Wright P (eds) (1997) The cytotoxics handbook. Radcliffe Medical Press, AbingdonGoogle Scholar
- 5.Dorr RT, Von Hoff DD (1994) Cancer chemotherapy book. McGraw–Hill, ColumbusGoogle Scholar
- 6.Graham MA, Gamelin E, Misset JL, Brienza S, Allain P, Boisdron-Celle, Krikorian A, Greenslade D, Bayssas M (1998) Proc Am Assoc Cancer Res 39:159Google Scholar
- 7.Mahnik S, Mader R, Fürhacker M (2002) ÖWAV Workshop: Arzneimittel in der aquatischen Umwelt, 26.9.2002, Universität für Bodenkultur Wien; Zytostatika im Abwasser. Wiener Mitteilungen 178:91–111Google Scholar
- 8.International Agency for Research on Cancer (IARC), (1987) Monographs on the Evaluation of Cancerogenic Risks to Humans, suppl 7, LyonGoogle Scholar
- 9.Gebel T (2000) AAAa. In: Zereini F, Alt F (eds) Anthropogenic platinum group element emissions. Springer Verlag, Berlin Heidelberg New York, pp 245–255Google Scholar
- 26.Lenz K, Hann S, Koellensperger G, Stefanka Zs, Stingeder G, Weissenbacher N, Mahnik SN, Fuerhacker M, J Environ Monit (submitted)Google Scholar
- 29.Stefánka Zs, Hann S, Koellensperger G, Stingeder G (2004) J Anal At Spectrom. DOI:10.1039/B402028FGoogle Scholar
- 31.Quantifying Uncertainty in Analytical Measurement (2000) EURACHEM, LondonGoogle Scholar
- 35.Tang X, Hayes II JW, Schroder L, Cacini W, Dorsey J, Elder RC, Tepperman K (1997) Met Based Drugs 4:97–109Google Scholar